TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival

L. Mu, D. Katsaros, L. Lu, M. Preti, A. Durando, R. Arisio, H. Yu

Research output: Contribution to journalArticle

Abstract

Transforming growth factor-β (TGF-β)-mediated signals play complicated roles in the development and progression of breast tumour. The purposes of this study were to analyse the genotype of TGF-β1 at T29C and TGF-β1 phenotype in breast tumours, and to evaluate their associations with IGFs and clinical characteristics of breast cancer. Fresh tumour samples were collected from 348 breast cancer patients. TGF-β1 genotype and phenotype were analysed with TaqMan® and ELISA, respectively. Members of the IGF family in tumour tissue were measured with ELISA. Cox proportional hazards regression analysis was performed to assess the association of TGF-β1 and disease outcomes. Patients with the T/T (29%) genotype at T29C had the highest TGF-β1, 707.9 pg mg-1, followed by the T/C (49%), 657.8 pg mg-1, and C/C (22%) genotypes, 640.8 pg mg-1, (P=0.210, T/T vs C/C and C/T). TGF-β1 concentrations were positively correlated with levels of oestrogen receptor, IGF-I, IGF-II and IGFBP-3. Survival analysis showed TGF-β1 associated with disease progression, but the association differed by disease stage. For early-stage disease, patients with the T/T genotype or high TGF-β1 had shorter overall survival compared to those without T/T or with low TGF-β1; the hazard ratios (HR) were 3.54 (95% CI: 1.21-10.40) for genotype and 2.54 (95% CI: 1.10-5.89) for phenotype after adjusting for age, grade, histotype and receptor status. For late-stage disease, however, the association was different. The T/T genotype was associated with lower risk of disease recurrence (HR=0.13, 95% CI: 0.02-1.00), whereas no association was found between TGF-β1 phenotype and survival outcomes. The study suggests a complex role of TGF-β1 in breast cancer progression, which supports the finding of in vitro studies that TGF-β1 has conflicting effects on tumour growth and metastasis.

Original languageEnglish
Pages (from-to)1357-1363
Number of pages7
JournalBritish Journal of Cancer
Volume99
Issue number8
DOIs
Publication statusPublished - Oct 21 2008

Fingerprint

Transforming Growth Factors
Genotype
Breast Neoplasms
Phenotype
Survival
Enzyme-Linked Immunosorbent Assay
Neoplasms
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor II
Survival Analysis
Insulin-Like Growth Factor I
Estrogen Receptors
Disease Progression
Regression Analysis

Keywords

  • Breast cancer
  • IGFs
  • Polymorphism
  • Survival
  • TGF-β1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival. / Mu, L.; Katsaros, D.; Lu, L.; Preti, M.; Durando, A.; Arisio, R.; Yu, H.

In: British Journal of Cancer, Vol. 99, No. 8, 21.10.2008, p. 1357-1363.

Research output: Contribution to journalArticle

Mu, L, Katsaros, D, Lu, L, Preti, M, Durando, A, Arisio, R & Yu, H 2008, 'TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival', British Journal of Cancer, vol. 99, no. 8, pp. 1357-1363. https://doi.org/10.1038/sj.bjc.6604689
Mu, L. ; Katsaros, D. ; Lu, L. ; Preti, M. ; Durando, A. ; Arisio, R. ; Yu, H. / TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival. In: British Journal of Cancer. 2008 ; Vol. 99, No. 8. pp. 1357-1363.
@article{6f4d27294ea046b58a3e0ae65da07e0b,
title = "TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival",
abstract = "Transforming growth factor-β (TGF-β)-mediated signals play complicated roles in the development and progression of breast tumour. The purposes of this study were to analyse the genotype of TGF-β1 at T29C and TGF-β1 phenotype in breast tumours, and to evaluate their associations with IGFs and clinical characteristics of breast cancer. Fresh tumour samples were collected from 348 breast cancer patients. TGF-β1 genotype and phenotype were analysed with TaqMan{\circledR} and ELISA, respectively. Members of the IGF family in tumour tissue were measured with ELISA. Cox proportional hazards regression analysis was performed to assess the association of TGF-β1 and disease outcomes. Patients with the T/T (29{\%}) genotype at T29C had the highest TGF-β1, 707.9 pg mg-1, followed by the T/C (49{\%}), 657.8 pg mg-1, and C/C (22{\%}) genotypes, 640.8 pg mg-1, (P=0.210, T/T vs C/C and C/T). TGF-β1 concentrations were positively correlated with levels of oestrogen receptor, IGF-I, IGF-II and IGFBP-3. Survival analysis showed TGF-β1 associated with disease progression, but the association differed by disease stage. For early-stage disease, patients with the T/T genotype or high TGF-β1 had shorter overall survival compared to those without T/T or with low TGF-β1; the hazard ratios (HR) were 3.54 (95{\%} CI: 1.21-10.40) for genotype and 2.54 (95{\%} CI: 1.10-5.89) for phenotype after adjusting for age, grade, histotype and receptor status. For late-stage disease, however, the association was different. The T/T genotype was associated with lower risk of disease recurrence (HR=0.13, 95{\%} CI: 0.02-1.00), whereas no association was found between TGF-β1 phenotype and survival outcomes. The study suggests a complex role of TGF-β1 in breast cancer progression, which supports the finding of in vitro studies that TGF-β1 has conflicting effects on tumour growth and metastasis.",
keywords = "Breast cancer, IGFs, Polymorphism, Survival, TGF-β1",
author = "L. Mu and D. Katsaros and L. Lu and M. Preti and A. Durando and R. Arisio and H. Yu",
year = "2008",
month = "10",
day = "21",
doi = "10.1038/sj.bjc.6604689",
language = "English",
volume = "99",
pages = "1357--1363",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival

AU - Mu, L.

AU - Katsaros, D.

AU - Lu, L.

AU - Preti, M.

AU - Durando, A.

AU - Arisio, R.

AU - Yu, H.

PY - 2008/10/21

Y1 - 2008/10/21

N2 - Transforming growth factor-β (TGF-β)-mediated signals play complicated roles in the development and progression of breast tumour. The purposes of this study were to analyse the genotype of TGF-β1 at T29C and TGF-β1 phenotype in breast tumours, and to evaluate their associations with IGFs and clinical characteristics of breast cancer. Fresh tumour samples were collected from 348 breast cancer patients. TGF-β1 genotype and phenotype were analysed with TaqMan® and ELISA, respectively. Members of the IGF family in tumour tissue were measured with ELISA. Cox proportional hazards regression analysis was performed to assess the association of TGF-β1 and disease outcomes. Patients with the T/T (29%) genotype at T29C had the highest TGF-β1, 707.9 pg mg-1, followed by the T/C (49%), 657.8 pg mg-1, and C/C (22%) genotypes, 640.8 pg mg-1, (P=0.210, T/T vs C/C and C/T). TGF-β1 concentrations were positively correlated with levels of oestrogen receptor, IGF-I, IGF-II and IGFBP-3. Survival analysis showed TGF-β1 associated with disease progression, but the association differed by disease stage. For early-stage disease, patients with the T/T genotype or high TGF-β1 had shorter overall survival compared to those without T/T or with low TGF-β1; the hazard ratios (HR) were 3.54 (95% CI: 1.21-10.40) for genotype and 2.54 (95% CI: 1.10-5.89) for phenotype after adjusting for age, grade, histotype and receptor status. For late-stage disease, however, the association was different. The T/T genotype was associated with lower risk of disease recurrence (HR=0.13, 95% CI: 0.02-1.00), whereas no association was found between TGF-β1 phenotype and survival outcomes. The study suggests a complex role of TGF-β1 in breast cancer progression, which supports the finding of in vitro studies that TGF-β1 has conflicting effects on tumour growth and metastasis.

AB - Transforming growth factor-β (TGF-β)-mediated signals play complicated roles in the development and progression of breast tumour. The purposes of this study were to analyse the genotype of TGF-β1 at T29C and TGF-β1 phenotype in breast tumours, and to evaluate their associations with IGFs and clinical characteristics of breast cancer. Fresh tumour samples were collected from 348 breast cancer patients. TGF-β1 genotype and phenotype were analysed with TaqMan® and ELISA, respectively. Members of the IGF family in tumour tissue were measured with ELISA. Cox proportional hazards regression analysis was performed to assess the association of TGF-β1 and disease outcomes. Patients with the T/T (29%) genotype at T29C had the highest TGF-β1, 707.9 pg mg-1, followed by the T/C (49%), 657.8 pg mg-1, and C/C (22%) genotypes, 640.8 pg mg-1, (P=0.210, T/T vs C/C and C/T). TGF-β1 concentrations were positively correlated with levels of oestrogen receptor, IGF-I, IGF-II and IGFBP-3. Survival analysis showed TGF-β1 associated with disease progression, but the association differed by disease stage. For early-stage disease, patients with the T/T genotype or high TGF-β1 had shorter overall survival compared to those without T/T or with low TGF-β1; the hazard ratios (HR) were 3.54 (95% CI: 1.21-10.40) for genotype and 2.54 (95% CI: 1.10-5.89) for phenotype after adjusting for age, grade, histotype and receptor status. For late-stage disease, however, the association was different. The T/T genotype was associated with lower risk of disease recurrence (HR=0.13, 95% CI: 0.02-1.00), whereas no association was found between TGF-β1 phenotype and survival outcomes. The study suggests a complex role of TGF-β1 in breast cancer progression, which supports the finding of in vitro studies that TGF-β1 has conflicting effects on tumour growth and metastasis.

KW - Breast cancer

KW - IGFs

KW - Polymorphism

KW - Survival

KW - TGF-β1

UR - http://www.scopus.com/inward/record.url?scp=53849129518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53849129518&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6604689

DO - 10.1038/sj.bjc.6604689

M3 - Article

C2 - 18827819

AN - SCOPUS:53849129518

VL - 99

SP - 1357

EP - 1363

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 8

ER -